TEST (BITE 3 – Módulo 4) – Scientific Bites

Test Summary

0 de 10 preguntas completadas

Preguntas:

Ya has completado este test anteriormente, así que no puedes volver a empezarlo.

Cargando Test…

Debes iniciar sesión o registrarte para empezar el test.

En primer lugar debes completar esto:

Resultados

Test completado. Se están registrando tus resultados.

Resultados

0 de 10 preguntas contestadas correctamente

Tu tiempo:

Has conseguido 0 de 0 punto(s), (0)

Respondido/a
Revisar

Pregunta 1 de 10

1. Pregunta
Which of the following sentences is false?
- Surgery should not be considered in patients presenting with a single metastasis and stable or absent extracranial disease
- Surgery has a limited role in patients with more than one brain metastasis, except when a large, symptomatic lesion is also present
- In the presence of multiple lesions, either stereotactic radiosurgery, WBRT, or the combination are usually preferred
Correcto

Incorrecto
Pregunta 2 de 10

2. Pregunta
The approach of brain metastases in breast cancer is determined by:
- The tumor subtypes
- Previous adjuvant treatment
- PDL-1 expression
Correcto

Incorrecto
Pregunta 3 de 10

3. Pregunta
Brain metastases are common during the course of HER2-positive metastatic breast cancer. For this reason:
- Patients with systemic disease that is not progressive at the time of diagnosis of brain metastases should not continue to receive the same systemic therapy
- They often occur despite optimal systemic control, likely because trastuzumab does not cross an intact blood-brain barrier
- MRI should be performed in the follow-up of HER2 + tumors
Correcto

Incorrecto
Pregunta 4 de 10

4. Pregunta
Which of the following sentences is true?
- In the LANDSCAPE trial, the combination of lapatinib and capecitabine was active in patients with previously untreated metastatic brain disease, but this regimen has not yet been compared with WBRT
- In the TBCRC 022 study, the combination of neratinib and capecitabine was associated with a PFS of 5.5 months in patients with refractory brain metastases and no prior treatment with lapatinib
- The use of tucatinib, trastuzumab, and capecitabine was associated with a 25% reduction in risk of CNS-PFS and a 20% reduction in risk of death overall compared to placebo, trastuzumab, and capecitabine
Correcto

Incorrecto
Pregunta 5 de 10

5. Pregunta
What is the best therapeutic option for patients with brain metastases and good performance status?
- Local therapy
- Targeted therapy for pi3K
- Liquid biopsy for phenotypic profiling
Correcto

Incorrecto
Pregunta 6 de 10

6. Pregunta
HER2CLIMB trial includes:
- Patients treated previously with trastuzumab, pertuzumab and lapatinib
- All patients have received local treatment previously
- Progressive disease after radiotherapy
Correcto

Incorrecto
Pregunta 7 de 10

7. Pregunta
Which iCDK has some efficacy for treating leptomeningeal carcinomatosis?
- Palbociclib
- Ribociclib
- Abemaciclib
Correcto

Incorrecto
Pregunta 8 de 10

8. Pregunta
ESMO guidelines recommends for HER2- breast cancer patients with progressive brain metastases:
- Chemotherapy
- Local treatment
- Best supportive care
Correcto

Incorrecto
Pregunta 9 de 10

9. Pregunta
Trastuzumab-deruxtecan…
- Crosses the brain barrier
- Has been approved by FDA as the first drug for treating breast cancer HER2 brain metastases
- The most frequent toxicity is thrombocytopenia
Correcto

Incorrecto
Pregunta 10 de 10

10. Pregunta
Which of the following drugs can cross the brain barrier?
- Carboplatin
- Vinorelbine
- Paclitaxel
Correcto

Incorrecto

Test Summary

Información

Resultados

Resultados

Categorías

1. Pregunta

2. Pregunta

3. Pregunta

4. Pregunta

5. Pregunta

6. Pregunta

7. Pregunta

8. Pregunta

9. Pregunta

10. Pregunta